All In Biotech

Drug Trial Radar · NCT03710915

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

Jan 12, 2019

Primary completion

Sep 28, 2022

Study completion Jun 28, 2023

Sponsor

Lead sponsor
HitGen Inc.Industry
Sponsor type
Industry
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.

Conditions

  • Multiple Myeloma
  • Relapsed and Refractory Multiple Myeloma

Interventions

  • HG146Drug

    HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose of HG146Time frame: Up to 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HitGen Inc

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.